Markets:

Overview

News

Currencies

International

Treasuries

Viridian Therapeutics, Inc. - Common Stock (NQ:VRDN)

17.06 +1.09 (+6.83%)

Streaming Delayed Price Updated: 12:56 PM EDT, May 20, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Viridian Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 Next >

Viridian Therapeutics Announces Completion of THRIVE-2 Enrollment for VRDN-001 in Patients with Chronic Thyroid Eye Disease (TED)

July 25, 2024

From Viridian Therapeutics, Inc.

Via Business Wire

Biogen Has Up To $10 Billion For Acquisitions; Why These Three Names Make Sense ↗

July 16, 2024

Biogen has $8 billion to $10 billion in dry powder for acquisitions. Here are three names the company could examine.

Via Investor's Business Daily

Expert Ratings For Viridian Therapeutics ↗

July 16, 2024

Via Benzinga

3 Small-Cap Stocks With Explosive 2X Growth Potential ↗

July 08, 2024

Discover three top high-growth small-cap stocks, fueled by potential rate cuts and promising prospects in the second half of 2024.

Via InvestorPlace

Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

July 03, 2024

From Viridian Therapeutics, Inc.

Via Business Wire

7 Analysts Assess Viridian Therapeutics: What You Need To Know ↗

June 06, 2024

Via Benzinga

Unveiling 4 Analyst Insights On Viridian Therapeutics ↗

March 20, 2024

Via Benzinga

12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗

June 11, 2024

Via Benzinga

Viridian Therapeutics Announces Details of Subcutaneous VRDN-003 Phase 3 Clinical Program for Patients with Active and Chronic Moderate-to-Severe Thyroid Eye Disease

June 11, 2024

From Viridian Therapeutics, Inc.

Via Business Wire

Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

June 06, 2024

From Viridian Therapeutics, Inc.

Via Business Wire

Navigating 6 Analyst Ratings For Viridian Therapeutics ↗

February 28, 2024

Via Benzinga

Viridian Therapeutics Announces Participation in Upcoming June Investor Conferences

May 31, 2024

From Viridian Therapeutics, Inc.

Via Business Wire

Viridian Therapeutics to Participate in Upcoming May Investor Conferences

May 10, 2024

From Viridian Therapeutics, Inc.

Via Business Wire

VRDN Stock Earnings: Viridian Therapeutics Beats EPS, Beats Revenue for Q1 2024 ↗

May 08, 2024

VRDN stock results show that Viridian Therapeutics beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024.

Via InvestorPlace

Viridian Therapeutics Highlights Recent Progress and Reports First Quarter 2024 Financial Results

May 08, 2024

From Viridian Therapeutics, Inc.

Via Business Wire

Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

May 03, 2024

From Viridian Therapeutics, Inc.

Via Business Wire

Viridian Therapeutics to Webcast First Quarter 2024 Financial Results on May 8, 2024

April 29, 2024

From Viridian Therapeutics, Inc.

Via Business Wire

Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

April 04, 2024

From Viridian Therapeutics, Inc.

Via Business Wire

Finding the Next Big Winners: 3 Stocks You Can Snag for Under $20 ↗

March 19, 2024

Although cheap stocks under $20 represent a higher-risk profile, the rewards could be massive if the spotlight shines on them.

Via InvestorPlace

Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

March 06, 2024

From Viridian Therapeutics, Inc.

Via Business Wire

Viridian Therapeutics to Participate in the Leerink Partners Global Biopharma Conference

March 05, 2024

From Viridian Therapeutics, Inc.

Via Business Wire

Viridian Therapeutics Highlights Recent Progress and Reports Fourth Quarter and Full Year 2023 Financial Results

February 27, 2024

From Viridian Therapeutics, Inc.

Via Business Wire

Viridian Therapeutics Appoints Jennifer Tousignant as Chief Legal Officer

February 16, 2024

From Viridian Therapeutics, Inc.

Via Business Wire

Viridian Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

February 06, 2024

From Viridian Therapeutics, Inc.

Via Business Wire

Here's Why Viridian Therapeutics (VRDN) Stock Is Moving ↗

January 18, 2024

Viridian Therapeutics shares are trading lower by 5.9% Thursday morning. The company announced pricing of an underwritten public offering.

Via Benzinga

Viridian Therapeutics Announces Pricing of Public Offering of Shares of Common Stock

January 17, 2024

From Viridian Therapeutics, Inc.

Via Business Wire

Viridian Therapeutics Announces Proposed Underwritten Public Offering of Common Stock and Preferred Stock

January 17, 2024

From Viridian Therapeutics, Inc.

Via Business Wire

Viridian Therapeutics to Present Key 2024 Corporate Priorities at J.P. Morgan Healthcare Conference

January 08, 2024

From Viridian Therapeutics, Inc.

Via Business Wire

Viridian Therapeutics to Webcast Presentation at the 42nd Annual J.P. Morgan Healthcare Conference

January 04, 2024

From Viridian Therapeutics, Inc.

Via Business Wire

ZimVie Agrees To Sell Its Spine Business, Joins United States Steel, PGT Innovations And Other Big Stocks Moving Higher On Monday ↗

December 18, 2023

U.S. stocks traded mostly higher, with the Nasdaq Composite gaining around 30 points on Monday.

Via Benzinga

Topics Stocks

< Previous 1 2 3 4 5 6 7 8 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.